首页> 外文OA文献 >Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS)

【2h】

Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS)

机译：比较贝伐单抗联合或不联合厄洛替尼作为晚期非小细胞肺癌（ATLAS）维持治疗的随机安慰剂对照IIIb期临床试验的生物标志物分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Kabbinavar Fairooz; Fehrenbacher Louis; Hainsworth John; Kasubhai Saifuddin; Kressel Bruce; Marsland Thomas; Patel Taral; Rubin Mark; White Leonard; Yang James Chih-Hsin; Klughammer Barbara; Colburn Dawn; Miller Vincent; Johnson Bruce E.;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS) [J] . KabbinavarF., FehrenbacherL., HainsworthJ., Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2014,第9期

机译：来自一项随机，安慰剂对照的IIIb期试验的生物标志物分析，比较了贝伐单抗与厄洛替尼联合或不联合厄洛替尼作为治疗晚期非小细胞肺癌（ATLAS）的维持疗法
2. ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer [J] . Bruce E. Johnson, Fairooz Kabbinavar, Louis Fehrenbacher, Journal of Clinical Oncology . 2013,第31期

机译：ATLAS：随机，双盲，安慰剂对照的IIIB期临床试验，比较在完成化学疗法后使用贝伐单抗和/或厄洛替尼或不使用厄洛替尼的贝伐单抗用于一线治疗晚期非小细胞肺癌
3. ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer [J] . Bruce E. Johnson, Fairooz Kabbinavar, Louis Fehrenbacher, Journal of Clinical Oncology . 2013,第31期

机译：阿特拉斯：随机，双盲，安慰剂控制，阶段IIIB试验比较Bevacizumab疗法或没有奥尔洛替尼，完成化疗后，用Bevacizumab进行先进的非小细胞肺癌的一线治疗
4. Effects of Erlotinib after Acquired Resistance to Gefitinib in Advanced Non-small-cell Lung Cancer [C] . Pan Jingjing, Shi Meiqi, Feng Jifeng Biomedical Engineering and Biotechnology (iCBEB), 2012 International Conference on . 2012

机译：吉非替尼耐药对晚期非小细胞肺癌患者的厄洛替尼治疗效果
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind placebo-controlled phase 3 trial [O] . Roy S Herbst, Rafat Ansari, Frederique Bustin, -1

机译：双盲安慰剂对照3期试验：贝伐单抗加埃罗替尼埃罗替尼与单独的标准一线化疗（测试版）的失败后晚期非小细胞肺癌的功效
7. Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non–Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial [O] . Gridelli Cesare, Bennouna Jaafar, de Castro Javier, 2011

机译：评估贝伐单抗联合铂类化学疗法一线治疗的晚期非鳞状非小细胞肺癌晚期贝伐单抗超越疾病进展的持续性的随机IIIb期试验：AvaALL的治疗原理和方案动态（MO22097）试用版

Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS)

著录项

引文网络

相似文献

相关主题

期刊订阅